InMed Pharmaceuticals Inc. (INM) Stock Analysis and Metrics

InMed Pharmaceuticals

NASDAQ: INM

$1.71 ▼ -0.14 (-7.57%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap7.12 Mn

P/E-1.36

Div. Yield0.00

Add ratio to table…

About

InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing proprietary small molecule drug candidates that act as preferential signaling ligands of the cannabinoid CB1 and CB2 receptors and other targets linked to human disease. The company also operates a wholly owned subsidiary BayMedica that manufactures and sells bulk rare cannabinoids for use in the health and wellness sector.

Revenue is generated from two main streams. The pharmaceutical segment aims to earn income through licensing partnerships, milestone payments, and future sales of approved drug candidates targeting Alzheimer’s disease, dry age related macular degeneration, and epidermolysis bullosa. The BayMedica segment derives revenue from business to business sales of bulk rare cannabinoids such as cannabichromene, cannabidivarin, tetrahydrocannabivarin, and cannabicitran to manufacturers of nutraceuticals, cosmetics, functional foods, beverages, and animal health products.

The company operates through the following segments: Pharmaceutical Therapeutics and BayMedica Commercial.

• Pharmaceutical Therapeutics: This segment focuses on the research development and preclinical and clinical advancement of proprietary small molecule drug candidates that modulate CB1 CB2 and other receptors to treat diseases with high unmet medical need including Alzheimer’s disease, dry age related macular degeneration, and epidermolysis bullosa.

• BayMedica Commercial: This segment manufactures and sells bulk rare cannabinoids such as cannabichromene, cannabidivarin, tetrahydrocannabivarin, and cannabicitran to business to business customers in the nutraceutical, cosmetic, functional food, beverage, and animal health industries.

InMed Pharmaceuticals Inc. occupies a niche position at the intersection of cannabinoid science and pharmaceutical development. In the Alzheimer’s disease space it competes with larger biotech firms such as Biogen Eli Lilly and Roche that focus on amyloid targeting antibodies but lack approved disease modifying therapies. The company’s advantage lies in its proprietary small molecule approach that may offer oral administration and a multi factorial mechanism of action involving CB1 CB2 and PPAR pathways. In the rare cannabinoid manufacturing arena BayMedica faces competition from other specialized chemical synthesis and biosynthesis firms but benefits from its integrated IntegraSyn platform and early mover status as a B2B supplier of non intoxicating rare cannabinoids.

The pharmaceutical segment’s prospective customers include pharmaceutical companies academic research institutions and patients who may eventually receive approved therapies. The BayMedica segment serves business to business clients such as manufacturers of dietary supplements topical cosmetics functional beverages and animal health supplements. These relationships are expected to support future revenue streams as the company advances its pipeline.

Investment Thesis

▲ Bull case

The merger with Mentari Therapeutics represents a strategic pivot that could transform InMed from a preclinical-stage cannabinoid-focused company into a late-stage migraine therapeutic developer with two differentiated pipeline assets targeting high unmet need, where current anti-CGRP therapies fail approximately two-thirds of patients to achieve a 50% reduction in monthly migraine days and fewer than one-third achieve 75% reduction, creating a large addressable market for superior efficacy solutions like MT-001 and MT-002 that act on validated complementary pathways; this shift leverages Mentari's strong scientific foundation, including Paragon Therapeutics-discovered assets with equal or superior in vitro potency to benchmarks and projected subcutaneous dosing convenience, positioning the combined company to capture significant share in a global migraine market exceeding one billion sufferers while avoiding the crowded CGRP monotherapy space.
The concurrent US$290 million oversubscribed private placement, backed by blue-chip investors including a16z Bio + Health, Venrock, Wellington Management, and Blackstone Multi-Asset Investing, provides more than sufficient capital to fund operations through 2028 without dilution concerns, de-risking the execution of key milestones such as first-in-human regulatory filings for MT-001 expected mid-2026 and MT-002 in 1Q 2027, with Phase 2a proof-of-concept data for MT-001 anticipated in 2028 and Phase 1 healthy volunteer data for MT-002 in 2027—timelines that are benchmarked to approved migraine therapies and supported by a clear regulatory path, reducing execution risk and enabling the combined company to advance its pipeline without near-term financing overhang.
Despite InMed shareholders owning only approximately 1.51% of the pro forma US$421.4 million equity value post-merger, the structure includes meaningful downside protection and upside participation mechanisms through potential Parent Legacy Transaction distributions, dividends, and contingent value rights, which entitle legacy InMed shareholders to proceeds from any monetization of InMed's pre-merger R&D programs (Alzheimer's, ocular, dermatological) post-closing, creating a call option on non-core assets that could generate additional value if successfully partnered or divested, thereby aligning long-term incentives and mitigating the perceived inequity of the exchange ratio while preserving optionality on InMed's historical pipeline.

The merger with Mentari Therapeutics represents a strategic pivot that could transform InMed from a preclinical-stage cannabinoid-focused company into a late-stage migraine therapeutic developer with two differentiated pipeline assets targeting high unmet need, where current anti-CGRP therapies fail approximately two-thirds of patients to achieve a 50% reduction in monthly migraine days and fewer than one-third achieve 75% reduction, creating a large addressable market for superior efficacy solutions like MT-001 and MT-002 that act on validated complementary pathways; this shift leverages Mentari's strong scientific foundation, including Paragon Therapeutics-discovered assets with equal or superior in vitro potency to benchmarks and projected subcutaneous dosing convenience, positioning the combined company to capture significant share in a global migraine market exceeding one billion sufferers while avoiding the crowded CGRP monotherapy space.
The concurrent US$290 million oversubscribed private placement, backed by blue-chip investors including a16z Bio + Health, Venrock, Wellington Management, and Blackstone Multi-Asset Investing, provides more than sufficient capital to fund operations through 2028 without dilution concerns, de-risking the execution of key milestones such as first-in-human regulatory filings for MT-001 expected mid-2026 and MT-002 in 1Q 2027, with Phase 2a proof-of-concept data for MT-001 anticipated in 2028 and Phase 1 healthy volunteer data for MT-002 in 2027—timelines that are benchmarked to approved migraine therapies and supported by a clear regulatory path, reducing execution risk and enabling the combined company to advance its pipeline without near-term financing overhang.
Despite InMed shareholders owning only approximately 1.51% of the pro forma US$421.4 million equity value post-merger, the structure includes meaningful downside protection and upside participation mechanisms through potential Parent Legacy Transaction distributions, dividends, and contingent value rights, which entitle legacy InMed shareholders to proceeds from any monetization of InMed's pre-merger R&D programs (Alzheimer's, ocular, dermatological) post-closing, creating a call option on non-core assets that could generate additional value if successfully partnered or divested, thereby aligning long-term incentives and mitigating the perceived inequity of the exchange ratio while preserving optionality on InMed's historical pipeline.

▼ Bear case

The merger effectively subordinates InMed's legacy cannabinoid-focused pipeline—comprising Alzheimer's, ocular, and dermatological programs—to Mentari's migraine therapeutics, with InMed shareholders retaining only ~1.51% ownership in the combined entity, raising concerns that the transaction prioritizes Mentari's investors and management at the expense of InMed's historical stakeholders, especially given the lack of recent earnings call transparency and the absence of any promotional emphasis on how InMed's legacy assets will be advanced post-merger, suggesting these programs may be neglected or divested at low value rather than integrated into a unified strategy.
Although the private placement provides funding through 2028, the clinical timelines for Mentari's lead programs are aggressive and unprecedented: MT-001 aims for Phase 2a proof-of-concept data by 2028, and MT-002 targets Phase 1 healthy volunteer data in 1Q 2027, yet both antibodies (anti-PACAP and bispecific anti-CGRP/PACAP) are first-in-class or best-in-class aspirations with no prior clinical validation in humans for PACAP inhibition, introducing significant scientific and regulatory risk given that migraine pathophysiology is complex and targeting novel pathways like PACAP has not yet yielded approved therapies, meaning success is far from guaranteed despite promising preclinical data.
The combined company will operate under the Mentari Therapeutics name and ticker, with Mentari's existing board—including Julie Bruno (Fairmount Growth Partner) and Michelle Pernice (Fairmount Operating Partner)—assuming full control, while InMed's leadership, including CEO Eric A. Adams, is not guaranteed any board seats, signaling a de facto change of control where InMed's public shell is being used as a vehicle for Mentari's advancement without reciprocal governance influence, increasing the risk that post-merger decisions will favor Mentari's agenda and legacy InMed shareholders will have minimal oversight or strategic input despite contributing the public market infrastructure.

The merger effectively subordinates InMed's legacy cannabinoid-focused pipeline—comprising Alzheimer's, ocular, and dermatological programs—to Mentari's migraine therapeutics, with InMed shareholders retaining only ~1.51% ownership in the combined entity, raising concerns that the transaction prioritizes Mentari's investors and management at the expense of InMed's historical stakeholders, especially given the lack of recent earnings call transparency and the absence of any promotional emphasis on how InMed's legacy assets will be advanced post-merger, suggesting these programs may be neglected or divested at low value rather than integrated into a unified strategy.
Although the private placement provides funding through 2028, the clinical timelines for Mentari's lead programs are aggressive and unprecedented: MT-001 aims for Phase 2a proof-of-concept data by 2028, and MT-002 targets Phase 1 healthy volunteer data in 1Q 2027, yet both antibodies (anti-PACAP and bispecific anti-CGRP/PACAP) are first-in-class or best-in-class aspirations with no prior clinical validation in humans for PACAP inhibition, introducing significant scientific and regulatory risk given that migraine pathophysiology is complex and targeting novel pathways like PACAP has not yet yielded approved therapies, meaning success is far from guaranteed despite promising preclinical data.
The combined company will operate under the Mentari Therapeutics name and ticker, with Mentari's existing board—including Julie Bruno (Fairmount Growth Partner) and Michelle Pernice (Fairmount Operating Partner)—assuming full control, while InMed's leadership, including CEO Eric A. Adams, is not guaranteed any board seats, signaling a de facto change of control where InMed's public shell is being used as a vehicle for Mentari's advancement without reciprocal governance influence, increasing the risk that post-merger decisions will favor Mentari's agenda and legacy InMed shareholders will have minimal oversight or strategic input despite contributing the public market infrastructure.

Subsegments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Subsegments Breakdown of Revenue (2025)

Subsegments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Subsegments Breakdown of Revenue (2025)

Subsegments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password